The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is: * Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress? * Will the transdiagnostic treatment program decrease transdiagnostic risk factors? * Will the transdiagnostic treatment program decrease the measured risk factors equally? * Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally? * Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors? * Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms? * Have the participants been able to generalize the skills taught in the program(qualitative)? * Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?
The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress. The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions. The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
300
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Region Norrbotten, Primary care
Luleå, Norrbotten County, Sweden
RECRUITINGAnxiety, Depression and Stress symptoms post-treatment
Measured using DASS-21
Time frame: 3 weeks post-treatment
Anxiety, Depression and Stress symptoms follow-up
Measured using DASS-21
Time frame: 6 months post-treatment
Anxiety sensitivity post-treatment
Measured using BSQ, fear of bodily sensations related to anxiety
Time frame: 3 weeks post-treatment
Anxiety sensitivity follow-up
Measured using BSQ, fear of bodily sensations related to anxiety
Time frame: 6 months post-treatment
Experiential avoidance post-treatment
Measured using AFQ-Y8, psychological flexibility
Time frame: 3 weeks post-treatment
Experiential avoidance follow-up
Measured using AFQ-Y8, psychological flexibility
Time frame: 6 months post-treatment
Mindfulness post-treatment
Measured using FFMQ, mindfulness
Time frame: 3 weeks post-treatment
Mindfulness follow-up
Measured using FFMQ, mindfulness
Time frame: 6 months post-treatment
Alexithymia post-treatment
Measured using TAS-20, mindfulness
Time frame: 3 weeks post-treatment
Alexithymia follow-up
Measured using TAS-20, mindfulness
Time frame: 6 months post-treatment
Generalization
Qualitative interview with a few selected patients to review their experience of the treatment, its effectiveness and their ability to use the techniques taught.
Time frame: 6 months post-treatment
Additional treatment
It will be recorded if patients sought additional care after single-session treatment as well as type of care.
Time frame: 6 months post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.